Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2026)
Caribou Biosciences (CRBU) reported Current Deferred Revenue of $994000.0 for Q1 2026, down 64.86% year-over-year from $2.8 million in Q1 2025, and down 47.55% on a QoQ basis from $1.9 million in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of Current Deferred Revenue data on file, last reported at $994000.0 in Q1 2026.
- Quarterly Current Deferred Revenue fell 64.86% year-over-year to $994000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $994000.0 (down 64.86% YoY) and the FY2025 annual result came in at $1.9 million, down 70.6% from the prior year.
- Current Deferred Revenue fell to $994000.0 in Q1 2026 per CRBU's latest filing, from $1.9 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $27.5 million in Q3 2022 and bottomed at $100000.0 in Q1 2022.
- The 5-year median for Current Deferred Revenue is $4.6 million (2025), against an average of $8.0 million.
- The widest annual swing landed in 2022, when Current Deferred Revenue surged 27358.0%; it then plunged 88.6% in 2024.
- Tracing CRBU's Current Deferred Revenue over 5 years: stood at $9.9 million in 2022, then retreated by 9.94% to $8.9 million in 2023, then slipped by 27.97% to $6.4 million in 2024, then sank by 70.6% to $1.9 million in 2025, then tumbled by 47.55% to $994000.0 in 2026.
- Per Business Quant, the three latest CRBU Current Deferred Revenue figures stand at $994000.0 (Q1 2026), $1.9 million (Q4 2025), and $4.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 994,000.00 |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 8.95 Mn |
| Sep 30, 2023 | 9.55 Mn |
| Jun 30, 2023 | 12.96 Mn |
| Mar 31, 2023 | 24.79 Mn |
| Dec 31, 2022 | 9.94 Mn |
| Sep 30, 2022 | 27.46 Mn |
| Jun 30, 2022 | 12.64 Mn |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 30.74 Mn |
| Sep 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 50,000.00 |
| Dec 31, 2020 | 161,000.00 |